GlaxoSmithKline (GSK) has agreed to acquire US-based cancer treatment developer Tesaro for $5.1bn.

GSK will acquire all issued and outstanding shares of Tesaro common stock for $75 a share, as part of the transaction.

Expected to be closed in the first quarter of 2019, the acquisition will improve GSK’s pharmaceutical business with the addition of Tesar’s oncology pipeline including Zejula, PD-1, TIM-3, and LAG-3.

Zejula is a PARP inhibitor used for the treatment of ovarian cancer while PD-1, TIM-3, and LAG-3 are immune checkpoint regulators.

Based in London, UK, GSK is a pharmaceutical and consumer healthcare company.

Shire’s $62bn takeover by Takeda Pharmaceutical has been approved by the company’s shareholders.

The companies received a conditional approval from the European Commission (EC) last month for the acquisition, which will allow Takeda to expand its presence in emerging drug markets and Japan, while strengthening its global pipeline for rare diseases.

“Shire’s $62bn takeover by Takeda Pharmaceutical has been approved by the company’s shareholders.”

The transaction is expected to be closed by January 2019, upon receiving necessary approvals from Shire’s shareholders and the Jersey Court.

Takeda is a Japanese pharmaceutical company with a presence in 70 countries worldwide, while US-based biotechnology company Shire focuses on developing biologic therapies for patients with rare diseases.

Global consumer goods company Procter & Gamble (P&G) has acquired Merck KGaA’s Consumer Health business unit for €3.4bn ($3.85bn).

Originally announced in April, the acquisition allows P&G to enhance its over-the-counter (OTC) brand portfolio and category footprint across 15 markets. It also strengthens the acquirer’s consumer healthcare commercial and supply capabilities.

Merck is a pharmaceutical company involved in developing medicines, vaccines, and animal health products.

Both the companies involved in the transaction are based in the US.